MedTrace Logo

Oral Carnosine for Neuromuscular Performance in Multiple Sclerosis

NCT03995810 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2020-03-24

No results posted yet for this study

Summary

Low levels of tissue carnosine and mitochondrial dysfunction appears to accompany multiple sclerosis (MS), with oral carnosine might be applicable to tackle impaired bioenergetics and oxidative stress in MS, and perhaps win back neuromuscular function. However, several formulations of carnosine have shown limited applicability due to restraints in brain delivery or tissue performance. No human studies so far evaluated the impact of innovative carnosine formulation (Karnozin EXTRA) in MS. Here, we will evaluate the impact of supplemental carnosine on neuromuscular performance, brain biomarkers of carnosine metabolism, and health-related quality of life in a case series of patients with MS.

Conditions

Interventions

DIETARY_SUPPLEMENT

Carnosine, capsulle, 2 g/day, 8 weeks

We will administer supplemental carnosine (2 grams per day) for 8 weeks

Sponsors & Collaborators

  • CarnoMed

    collaborator UNKNOWN

  • University of Novi Sad, Faculty of Sport and Physical Education

    lead OTHER

Principal Investigators

  • Sergej Ostojic, MD, PhD · University of Novi Sad

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-15
Primary Completion
2019-11-01
Completion
2019-12-01

Countries

  • Serbia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03995810 on ClinicalTrials.gov